Authors: | Roeker, L. E.; Han, Y.; Teschemaker, A.; Mato, A. R.; Thompson, M. C. |
Title: | BTK inhibitors versus venetoclax as first- or second-line therapy in chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world evidence study |
Keywords: | adult; controlled study; human tissue; aged; major clinical study; drug efficacy; monotherapy; rituximab; follow up; letter; protein bcl 2; cohort analysis; retrospective study; monoclonal antibody; cd20 antigen; immunoglobulin heavy chain; drug combination; drug therapy; chronic lymphatic leukemia; disease exacerbation; adverse drug reaction; chronic lymphocytic leukemia; clinical outcome; second-line treatment; ofatumumab; drug comparison; propensity score; chemoimmunotherapy; small lymphocytic lymphoma; ibrutinib; human; male; female; obinutuzumab; venetoclax; ecog performance status; acalabrutinib; bruton tyrosine kinase inhibitor; zanubrutinib; real-world evidence |
Journal Title: | American Journal of Hematology |
Volume: | 100 |
Issue: | 4 |
ISSN: | 0361-8609 |
Publisher: | John Wiley & Sons, Inc. |
Date Published: | 2025-04-01 |
Start Page: | 720 |
End Page: | 723 |
Language: | English |
DOI: | 10.1002/ajh.27639 |
PUBMED: | 39960132 |
PROVIDER: | scopus |
PMCID: | PMC11886488 |
DOI/URL: | |
Notes: | Letter -- MSK Cancer Center Support Grant (P30 CA008748) acknowledged in PubMed and PDF -- MSK corresponding author is Lindsey Roeker -- Source: Scopus |